Clearside Biomedical Gains Momentum in China with ARCATUS Approval Clearside Biomedical's partner, Arctic Vision, has received regulatory acceptance in China for ARCATUS, targeting uveitic macular edema. This marks a significant step for Clearside, leveraging its innovative SCS Microinjector technology. The Chinese market, with millions of potential patients, poses a promising revenue opportunity for the biopharma company.1